Nuvation Bio Inc. (NUVB) Stock Analysis and Metrics

Sector: Healthcare Industry: Biotechnology CIK: 0001811063

P/B 11.32

P/E -16.96

P/S 137.89

Market Cap 3.69 Bn

ROIC (Qtr) -41.96

Div Yield % 0.00

Rev 1y % (Qtr) 1,704.68

Total Debt (Qtr) 208.15 Mn

Debt/Equity (Qtr) 0.64

About

Nuvation Bio Inc., a prominent player in the biopharmaceutical industry, is making waves in the development of innovative therapies targeting severe unmet medical needs in oncology. With a strong foundation in medicinal chemistry and a commitment to delivering meaningful benefits to patients, Nuvation Bio is at the forefront of creating novel small molecule BET inhibitors. At the heart of Nuvation Bio's operations is the development of BET inhibitors, specifically targeting the BRD4 protein, which plays a pivotal role in epigenetic regulation...

Nuvation Bio Inc., a prominent player in the biopharmaceutical industry, is making waves in the development of innovative therapies targeting severe unmet medical needs in oncology. With a strong foundation in medicinal chemistry and a commitment to delivering meaningful benefits to patients, Nuvation Bio is at the forefront of creating novel small molecule BET inhibitors.

At the heart of Nuvation Bio's operations is the development of BET inhibitors, specifically targeting the BRD4 protein, which plays a pivotal role in epigenetic regulation of gene expression. This focus has led to the creation of NUV-868, a BD2-selective oral small molecule BET inhibitor designed to reduce the therapeutic limiting toxicities of BRD4 inhibitors currently in development. NUV-868 has demonstrated promising efficacy and safety in preclinical studies and is being evaluated in combination with PARP inhibitors and AR-directed therapies for treating advanced solid tumors.

NUV-868's favorable safety profile, with reduced toxicity compared to non-selective BET inhibitors, is a significant advantage for patients. In a Phase 1 monotherapy dose escalation study, NUV-868 was found to be well-tolerated, with no dose-limiting toxicities observed. This highlights Nuvation Bio's ability to rapidly advance product candidates through clinical trials and deliver differentiated therapies.

In addition to NUV-868, Nuvation Bio's pipeline includes other product candidates, such as NUV-1511. This DDC platform candidate combines tumor-targeting specificity with the anti-cancer activity of known oncology agents, demonstrating potent anti-tumor activity in preclinical studies. NUV-1511 is currently being evaluated in a Phase 1/2 dose study.

Nuvation Bio's competitive advantages lie in its expertise in medicinal chemistry, rapid clinical trial advancement, and focus on developing novel and differentiated therapies. Key competitors in the BET inhibitor space include Pfizer, Novartis, and Roche, but Nuvation Bio's unique approach and commitment to innovation set it apart.

The company's customers include oncology-focused pharmaceutical companies, research institutions, and clinical trial sites. Nuvation Bio's products are designed to be used in combination with other cancer therapies, such as PARP inhibitors and AR-directed therapies, to treat various types of cancer. This approach ensures that Nuvation Bio's offerings cater to the diverse needs of patients and healthcare providers alike.

Stock Price Chart

Analysis

Pros

Healthy cash reserves of 98.90M provide 7.34x coverage of short-term debt 13.47M, demonstrating strong liquidity position and minimal refinancing risk.
Strong tangible asset base of 589.88M provides 2.83x coverage of total debt 208.15M, indicating robust asset backing and low credit risk.
Short-term investments of 450.15M provide solid 11.45x coverage of other current liabilities 39.30M, indicating strong liquidity.
Strong free cash flow of (190.25M) provides 23.51x coverage of acquisition spending (8.09M), indicating disciplined M&A strategy.
Tangible assets of 589.88M provide robust 15.01x coverage of other current liabilities 39.30M, indicating strong asset backing.

Cons

Operating cash flow of (190M) barely covers its investment activities of 64.21M, with a coverage ratio of -2.96, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
Investment activities of 64.21M provide weak support for R&D spending of 110.11M, which is 0.58x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
Cash reserves of 98.90M provide limited coverage of acquisition spending of (8.09M), which is -12.22x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
Short-term investments of 450.15M significantly exceed cash reserves of 98.90M, which is 4.55x, indicating potentially excessive yield-seeking behavior at the expense of liquidity.
Free cash flow of (190.25M) provides weak coverage of capital expenditures of 252000, with a -754.95 ratio suggesting additional external financing needs for growth initiatives.

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	SMMT	Summit Therapeutics Inc.	1,444.63 Bn	-1,567.50	0.00	0.01 Bn
2	ONC	BeOne Medicines Ltd.	454.35 Bn	6,628.00	91.37	1.90 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	117.46 Bn	31.96	10.02	1.83 Bn
4	REGN	Regeneron Pharmaceuticals, Inc.	76.16 Bn	16.64	5.35	2.71 Bn
5	ALNY	Alnylam Pharmaceuticals, Inc.	65.40 Bn	1,501.10	20.37	3.21 Bn
6	ARGX	Argenx Se	55.14 Bn	36.60	28,753.46	-
7	BNTC	Benitec Biopharma Inc.	45.94 Bn	-1,098.33	0.00	0.00 Bn
8	INSM	INSMED Inc	39.34 Bn	-33.23	88.01	0.74 Bn

Industry Comparisons

Current Valuation

Metric	Value	Industry
EV to Assets	6.06	12.89
EV to Cash from Ops.	-19.18	21.72
EV to Debt	17.50	787.59
EV to EBIT	-17.32	-9.31
EV to EBITDA	-15.75	6.53
EV to Free Cash Flow [EV/FCF]	-19.15	20.53
EV to Market Cap	0.99	69.15
EV to Revenue	136.22	210.93
Price to Book Value [P/B]	11.32	22.97
Price to Earnings [P/E]	-16.96	-10.65

Dividend Metrics

Metric	Value	Industry
Dividend Coverage Ratio	0.00	-11.87
Dividend Payout Ratio %	0.00	0.16
Dividend per Basic Share	0.00	0.01
FCF Dividend Payout Ratio %	0.00	-0.14
Interest Coverage	-29.64	836.78

Growth Metrics

Metric	Value	Industry
Capex Growth (1y) %	-44.83	-26.81
Cash and Equivalents Growth (1y) %	229.26	732.55
Dividend Growth (1y) %	0.00	0.01
EBIAT Growth (1y) %	60.46	-47.24
EBITDA Growth (1y) %	58.63	-1.56
EBIT Growth (1y) %	60.46	-56.70
EBT Growth (1y) %	59.14	-13.21
EPS Growth (1y) %	77.52	-28.22
FCF Growth (1y) %	-91.56	-31.86
Gross Profit Growth (1y) %	2,173.29	225.74

Liquidity Ratios

Metric	Value	Industry
Asset Utilization Ratio	0.04	0.14
Cash Payout Ratio	0.00	0.00
Cash Ratio	1.45	3.86
Current Ratio	8.48	7.28
Debt to Equity Ratio	0.64	0.40
Interest Cover Ratio	-29.64	836.78
Times Interest Earned	-29.64	836.78

Profitability

Metric	Value	Industry
EBITDA Margin %	-780.40	-18,142.41
EBIT Margin %	-786.53	-18,487.15
EBT Margin %	-813.07	-19,390.53
Gross Margin %	54.30	-7.55
Net Profit Margin %	-813.10	-19,341.07

Nuvation Bio Inc. (NYSE: NUVB)